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Background: Multislice computed tomography (MSCT) increased detection of solitary pulmonary 
nodules (SPNs), changing the management based on radiological and clinical factors. When 18-fluorine 
fluorodeoxyglucose positron emission tomography combined with computed tomography (18F-FDG-PET/CT) 
was considered for the evaluation of nodules, the maximum standardized uptake value (SUVmax) more than 2.5 
is used frequently as a cut off for malignancy. The purpose of this study is to evaluate SUVmax PET/CT and 
pulmonary attenuation patterns at MSCT in patients with SPN according to morphological and pathological 
characteristics of the lesion. 
Methods: A retrospective study on 1,592 SPN patients was carried out following approval by the Italian 
Registry of VATS Lobectomies. 
Results: All patients underwent VATS lobectomy. On histologic examination, 98.1% had primary or 
second metachronous primary lung cancers. In addition, 10.7% presented occult lymph node metastases  
(pN1 or pN2) on histological examination. Nodule attenuation on CT was associated with the histology of 
the lesion (p= 0.030); in particular, pure ground glass opacities (pGGOs) and partially solid nodules were 
related to adenocarcinomatous histotypes. Conversely, a significant relationship between SUVmax and age, 
nodule size, pathological node status (pN) was found (P=0.007, P=0.000 and P=0.002 respectively). 
Conclusions: Nodule attenuation can predict the histology of the lesion whereas SUVmax may relate to 
the propensity to lymph node metastases.
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Introduction
A solitary pulmonary nodule (SPN) is a single radiological, 
round and well circumscribed pulmonary opacity less 
than 30 mm in diameter surrounded by aerated, non 
atelectatic parenchyma and without associated lymph node 
enlargement, pneumonia and pleural effusions (1). Most 
SPNs are incidentally found from 0.09% to 7% on chest 
imaging studies (2). In a report by the Early Lung Cancer 
Action Project, non-calcified nodules were detected at 
low-dose chest CT in 23% of the patients (233 of 1,000 
patients); malignancy was found in 27 of 1000 patients (2.7%) (3). 
Expectedly, cancer prevalence varies considerably according 
to the evaluated population subgroup. In lung cancer 
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Figure 1 Inclusion criteria and study design.
Number of patients from the VATS 
Italian registry: 2,006
CT exclusion criteria:
- N+: 126 patients
- M+: 16 patients
PET exclusion criteria:
- N+: 143 patients
- M+: 13 patients
Pathological exclusion criteria:
- M+: 18 patients
1,592 enrolled patients 
screening studies, the malignancy rates range between 2% 
and 13% reaching up to 82% in high risk patients (4). The 
widespread use of CT and multislice computed tomography 
(MSCT) has increased the detection of solid and subsolid 
nodules. The latter are characterized by a component with 
higher ground glass attenuation than lung parenchyma but 
lower than the mediastinal window (5). In addition, subsolid 
nodules may have a pure ground glass attenuation (pure 
ground glass opacities, pGGOs) and a mixed solid ground 
glass attenuation (partially solid ground glass opacities, 
psGGOs). The etiology of SPNs is broad and includes 
both benign (such as caused by infection, inflammation or 
hemorrhage) and malignant disease (such as lung cancer and 
pulmonary metastases). At high MSCT, there is considerable 
overlap in the assessment of benign and malignant SPN 
characteristics (6). However, specific morphological 
features are useful in determining malignant potential 
and among these, nodule attenuation is an important 
morphological pattern. The maximum standardized uptake 
value (SUVmax) of 18-fluorine fluorodeoxyglucose positron 
emission tomography combined with computed tomography 
(18F-FDG-PET/CT) more than 2.5 is used frequently as a cut 
off for malignancy (7). The aim of this study is to evaluate 
18F-FDG-PET/CT SUVmax and MSCT pulmonary 
density (solid vs. subsolid) in SPN patient according to 
their morphological and pathological patterns, in order to 
establish the radiological targeted features of malignancy. 
Methods
A retrospective study including 2,006 patients with SPN 
from January 2014 to May 2016 was carried out after 
approval by the Italian Registry of VATS Lobectomies. 
All  pat ients  received complete  imaging work-up 
(whole body CT and whole body PET/CT). SPNs were 
defined as nodules detected in the absence of hilar-
mediastinal lymphadenopathy or metastases on CT 
or PET/CT and in the absence of histopathological 
diagnosis of metastases (pM+) (Figure 1). Eight-hundred 
ninety-five males and 697 females with a mean age 
of 67.15±8.90 (range, 22.0–89.0 years) were enrolled. 
Demographic and clinical data are summarized in Table 1. 
One-thousand ninety-six patients (68.8%) presented at 
CT a less than 20 mm SPN, with a slight predominance 
for the right lung (984, 61.8%). Concerning CT nodule 
attenuation, 1,272 patients (79.9%) showed solid solitary 
pulmonary nodules (sSPNs), 291 patients (18.3%) psGGOs 
and 29 patients (1.8%) a pGGOs. The mean SUVmax 
was 4.11±4.80 (range, 0–31). Preoperative histological 
assessment was attempted by fine-needle aspiration biopsy 
(FNAB) in 892 patients (56.03%), endobronchial ultrasound 
biopsy (EBUS) in 27 patients (1.69%) and endoscopic 
ultrasonography (EUS) in 1 (0.06%), with a detection rate 
of 79.37% (708 out of 892), 37.03% (10 of 27) and 0% (0 of 1), 
respectively. Statistical analysis was performed using SPSS 
version 20.0 software for Windows (IBM, Chicago, USA). 
Continuous variables were expressed as absolute value, 
simple percentages, means and standard deviations, whereas 
categorical ones in terms of frequency and percentage. 
Statistical differences or correlations between cohorts were 
evaluated with Spearman’s correlation both for categorical 
and continuous variables, while for multivariate analysis 
unpaired t-test and Mann-Whitney U-test were evaluated. 
All risk factors were correlated with SUVmax, histology and 
lymph node status (N) using both bivariate and multivariate 
analysis and a P value <0.05 was considered statistically significant.
Results
All 1,592 patients underwent VATS lobectomy; a complete 
hilar-mediastinal lymphadenectomy was added in 1,120 (70.4%). 
On histologic examination, 98.1% (1,562 patients) had 
primary or secondary lung cancers and 1.9% (30 patients) 
had a benign disease. Primary adenocarcinoma was the 
predominant histotype (1,097, 68.9%), followed by other 
carcinomas and neuroendocrine tumors (12.8% and 10.2%, 
respectively). In addition, 10.7% presented occult lymph 
node metastases (pN1 or pN2) on histologic evaluation. 
Furthermore, lymph node micrometastases were reported 
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Table 1 SPN population: demographic, radiological and pathological characteristics
Clinical data N % Mean Interval SD
Gender
Male 895 56.2
Female 697 43.8
Age 67.15 22.0–89.0 8.90
Nodule size (CT)
<20 mm 1,096 68.8
20–30 mm 496 31.2
Nodule side (CT)
Right 984 61.8
Left 608 38.2
Nodule density (CT)
Solid 1,272 79.9
Partially solid GGO 291 18.3
Pure GGO 29 1.8
SUVmax (PET) 4.11 (0–31.0) 4.80
Preoperative histology
Yes 718 45.1
No 874 54.9
Type of lesion
Benign 30 1.9
Malignant 1,562 98.1
Histology cohorts
Benign diseases 30 1.9 (TBC n.3, Pseudotumor n.4, Other inflammatory diseases n.7, 
Hamartoma n.9, Hamartochondroma n.7)
Adenocarcinomas 1,097 68.9 (AAH n.29, AIS n.35, MIA n.164, Invasive adenocarcinoma n. 857, 
Adenoidocystic carcinoma n.12)
Carcinomas 204 12.8 (Squamous carcinoma n.203)
Neuroendocrine tumors 162 10.2 (Typical carcinoid n.91, Atypical carcinoid n.52, Large cell carcinoma 
n.14, SCLC n.5)
Other primary neoplasms 27 1.7 (Lymphoma n.6, Carcinosarcoma n.2, NSCLC NAS 19)
Metastases 72 4.5
Surgical approach
Anterior according Copenhagen 1,203 75.6
Anterior according D’Amico 182 11.4
Lateral according McKenna 76 4.8
Posterior according Walker 3 0.2
Totally endoscopic according Gossot 31 1.9
Uniportal according Gonzalez Rivas 97 6.1
Conversion 129 8.1
Table 1 (continued)
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in 3.0% (Table 1). Bivariate analysis between independent 
factors and SUVmax is reported in Table 2 while the 
correlation between independent factors, histology and 
SUVmax is described in Table 3. Nodule attenuation on 
CT was associated with the nature of lesion (P=0.030). 
In particular, pGGOs and partially solid nodules were 
related to adenocarcinomatous histotypes with different 
statistical strength (Figure 2). Specifically, pre-invasive 
lesions [such as atypical adenomatous hyperplasia (AAH) 
and adenocarcinoma in situ (AIS)] occurred preferentially 
as psGGOs while minimally invasive or invasive ones were 
detected as solid nodules (Table 4). Finally, the same nodule 
attenuation on CT presented a strong statistical correlation 
with the propensity for lymph node metastasis (P=0.000), 
albeit the comparison of pGGOs to solid nodules did not 
confirm these findings. In fact, the involvement of the 
N1 and the N2 compartments were noted in 5.58% and 
3.48% in pGGO and psGGO patients, respectively (Table 5).
Discussion
From a clinical standpoint, the management of SPN is 
controversial (4,5,8-11). Imaging with 18F-FDG-PET is 
a well-established indication for the evaluation of SPNs. 
In current practice, a semi-quantitative determination 
of FDG avidity calculated by standard uptake value in a 
region of interest (ROI) is the most common method to 
assess pulmonary nodules. FDG uptake on PET can be 
qualitatively and semi-quantitatively evaluated. Visual 
assessment is based upon comparison between FDG lesion 
uptake and mediastinum (12), but nodules with similar FDG 
uptake to the mediastinal pool are challenging; for these 
reasons, a 2.5 cut off the SUVmax has been used for the 
establishment of malignancy. However, FDG and its avidity 
is not tumor-specific and an increased uptake is reported in 
benign diseases (13-16). On the other hand, malignancies 
can be poorly avid leading to mistaken conclusions or 
interpretation of findings (17-19). In addition, it must be 
considered that many factors influence the SUV such as 
ROI itself, volume effects and corrections, reconstruction 
methods and body size (20). The combination of computed 
tomography and PET showed an excellent performance 
in the SPN classification (4,21). In this setting, the results 
of the present study indicate that there is a correlation 
between the nodule size and the SUVmax value (P=0.000) 
which is consistent with the conclusions by Khalaf et al. (22). 
Table 1 (continued)
Clinical data N % Mean Interval SD
Type of resection
Upper lobectomy 912 57.3
Middle lobectomy 127 8.0
Lower lobectomy 538 33.8
Upper bilobectomy 8 0.5
Lower bilobectomy 7 0.4
LN dissection 1,577 99.1
LND type
RND 1,120 70.4
Sampling 457 28.7
N resected LN 13.33 (0–64.0) 7.93
N status
N0 1,392 87.4
N1 92 5.8
N2 78 4.9
N micrometastases 48 3.0
SPN, solitary pulmonary nodule; CT, computed tomography; GGO, ground glass opacities; PET, positron emission tomography; LN, lymph 
node; LND, lymph node dissection; RND, radical node dissection.
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Reasons are to be found in the nodule diameter which 
influences SUV; in fact, small benign pulmonary nodules 
can present average SUV similar to malignant ones. 
Moreover, a 2.5 SUVmax threshold in small nodules can 
lead to false positive PET scans. In our study, the SUVmax 
was 3.300±3.303 for benign diseases, 3.25±4.01 for invasive 
adenocarcinomas and 6.51±6.26 for squamous carcinomas; 
no malignant nodules presented a mean SUVmax of 
less than 2.5. Furthermore, we noticed two interesting 
relationships: (I) in a fashion similar to the results presented 
by Nahmias et al. (23), we found a significant correlation 
between SUVmax and patients’ age (P= 0.016); (II) in 
agreement with Xu et al. (24), we also observed a significant 
correlation between SUVmax and prediction of lymph 
node metastases on histological specimens (P=0.001). Lin 
et al. (25) recently reported 284 consecutive cN0 patients 
with peripheral NSCLC who underwent PET/CT scans 
followed by pulmonary resections in order to identify 
predictors of occult lymph node metastases. In 8.5% lung 
cancers diagnosed N0 by PET/CT, the Authors revealed 
pathological N2 metastases and the SUVmax was the unique 
independent risk factor for occult N2 disease (25). Similar 
results were reported by Park et al. (26) in patients with 
less than 30 mm NSCLC, confirming SUVmax as a useful 
predictive marker for tumor aggressiveness. According to 
our inclusion criteria (cN0 and cM0), the only independent 
variable affecting staging is T value. This parameter is 
function of the nodule’s size (27) according to which all 
malignant solitary nodules would be pT1 (T1a and T1b). 
However, assuming this criterion as constant, the only 
interfering variable would be the topographic aspect. In 
fact, in the staging process, the T component increases as 
it is located either distal (T3 pleurae) or proximal to the 
hilum (T2b main bronchus or T4 mediastinum). For these 
reasons, the correlation between the changes in staging 
and the SUVmax values would only be an expression of 
different positions and relationships of the nodule itself. 
In our study, we showed no overall significant correlation 
between histological findings and SUVmax (P=0.586). 
Davidson et al. (28) suggested that squamous pulmonary 
carcinoma presented a significantly greater uptake on 
PET/CT than adenocarcinoma. We found a mean SUVmax 
of 6.51±6.26 for squamous carcinomas and of 4.63±3.97 
for adenocarcinomas (both pre-invasive and invasive 
patterns; P=0.132). On the other hand, considering only 
the squamous carcinoma and invasive adenocarcinoma, 
a significant difference was noted (P=0.013) whereas 
when only adenocarcinoma subtypes were considered, no 
statistical correlation in SUVmax was found (P=0.324). 
In particular,  contrary to what already presented 
in the literature, AAH, AIS and minimally invasive 
adenocarcinoma (MIA) presented higher uptake values 
rather than invasive adenocarcinomas (4.86, 5.00, 5.42 and 
3.25, respectively). Chiu et al. (29), in a study on 142 patients 
with 153 lung primary adenocarcinomas, showed that 
FDG uptake differs according to various histological 
subtypes of lung adenocarcinoma due to differences in 
GLU-1 expression. Nakamura et al. (30), in a study on 
255 patients, also reported similar results concluding that 
SUVmax was closely associated with histologic subtype 
in resected adenocarcinoma specimens. Specifically, 
pre-invasive lesions (such as AAH and AIS) occurred as 
ground glass opacities, while invasive ones were detected 
as solid nodules. These changes would seem therefore 
to correlate with the cytoarchitectonic reorganization 
of malignant SPNs from pre-invasive to invasive forms. 
Kobayashi et al. (31), in a review on ground glass opacities, 
also showed that atypical adenomatous hyperplasia and 
adenocarcinoma in situ typically develop as pure GGOs, 
whereas more advanced adenocarcinomas may include a 
larger solid component within the GGO region. Similar 
trends were also reported between density of lesion and 
propensity for lymph node metastases (P=0.000). In 
particular, pGGOs did not present propensity to node 
metastases when compared to solid nodules. Ye et al. (32), 
retrospectively analyzed a series of 271 patient with small 
nodules of peripheral lung adenocarcinoma and were able 
Table 2 Bivariate analysis (Spearman’s correlation) between independent 
factors and SUVmax in solitary pulmonary nodule patients
Factor
SUVmax
Spearman R P
Age* 0.068 0.007
Nodule size CT** 0.164 0.000
Nodule density CT** 0.041 0.102
Stage** −0.003 0.918
Type of lesion** −0.021 0.418
N status** 0.077 0.002
Number of resected LN* −0.092 0.103
LN micrometastases** −0.083 0.167
*, continuous variable; **, catgorical variable. CT, computed 
tomography; LN, lymph node.
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Table 3 Multivariate analysis between independent factors and SUVmax in solitary pulmonary nodule patients
Subjects N Mean SD
CI 95%
P
Min Max
Agea 1,592 67.14 8.891 65.71 66.58 0.000
Nodule size CTa 0.000
<20 mm 1,096 3.48 4.191 3.23 3.73
20–30 mm 496 5.59 5.684 4.99 5.99
Nodule density CTb 0.107
Solid 1,272 4.12 4.939 3.84 4.39
psGGO 291 4.24 4.230 3.76 4.73
pGGO 29 2.28 3.316 1.01 3.54
Stageb 0.081
IA 1,429 4.06 4.708 3.82 4.30
IB 95 4.14 5.760 2.96 5.31
IIA 4 10.25 8.655 −3.52 24.02
IIB 29 5.10 4.923 3.23 6.98
IIIA 5 5.40 3.975 0.46 10.34
Type of lesiona 0.353
Benign 30 3.30 3.303 3.23 3.73
Malignant 1,562 4.12 4.820 4.99 5.99
N statusb 0.004
N0 1,392 3.99 4.727 3.74 4.23
N1 92 4.97 5.562 3.82 6.12
N2 78 5.55 5.244 4.37 6.73
LN micrometastasesa 0.223
Yes 48 4.94 5.583 3.32 6.56
No 1,544 4.08 4.769 3.84 4.32
a, unpaired t-test (χ2); b, Mann-Whitney U-test. CT, computed tomography; psGGO, partially solid ground glass opacities; pGGO, pure 
ground glass opacities; LN, lymph node.
to demonstrate a significant difference in lymph node 
metastasis between the aforesaid cohorts concluding that 
pure GGOs were not associated to lymph node metastasis. 
Moreover, Kim et al. (33) emphasized the low incidence 
of lymph node (n. 2, 2.25%) and distant metastases 
(n. 3, 3.37%) in evaluating 89 patients with 134 pGGNs. 
According to these results, Ye et al. (34) recently suggested 
to avoid lymph node dissection in lung adenocarcinoma 
pure GGO cT1aN0M0 patients. In our study, the 
limitations are two-fold: (I) this is a non homogeneous 
series from a national wide registry of “VATS Lobectomies” 
performed for both benign and malignant conditions; 
(II) no control group could be established.
Conclusions
SPNs are clinically challenging and their management is 
affected by the probability of malignancy defined according 
to history, morphological and radiological features. In fact, 
nodules attenuation, double-volume time and standardized 
uptake value may entail important predictive and prognostic 
significance. In particular, we found that SUVmax was 
positively correlated with the potential for lymphatic 
metastasis and the clinical stage. On the other hand, the 
nodules attenuation patterns should be carefully considered 
especially when evaluating sub solid nodules as their 
variation could be an expression of neoplastic progression. 
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Figure 2 Nodule attenuation pattern vs. histology in solitary pulmonary nodule patients (simple bar plot): pulmonary subsolid nodules 
usually relate to adenocarcinomatous pattern.
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Table 4 Histological specimen vs. nodule attenuation pattern at CT
Histological specimen
Nodule density CT
Total
Solid
Partially 
solid GGO
Pure 
GGO
MIA 126 30 8 164
AIS 0 34 1 35
AAH 3 26 0 29
Invasive adenocarcinoma 716 122 19 857
Squamous carcinoma 168 35 0 203
Typical carcinoid 83 8 0 91
Atypical carcinoid 45 7 0 52
Large cell carcinoma 11 3 0 14
SCLC 4 1 0 5
Lymphoma 6 1 0 7
Metastasis 58 14 0 72
Adenoidocystic carcinoma 10 2 0 12
Carcinosarcoma 2 0 0 2
NSCLC NAS 14 4 1 19
Benign diseases 26 4 0 30
CT, computed tomography; GGO, pure ground glass opacities; 
MIA, minimally invasive adenocarcinoma; AIS, and adenocarcinoma 
in situ; AAH, atypical adenomatous hyperplasia.
Table 5 Nodule attenuation gradient at CT vs. propensity to lymph 
node metastases in SPN patients
Nodule density CT
N
Total P
0 1 2
Solid 1,102 76 68 1,246 0.000
Partially solid GGO 261 16 10 287
Pure GGO 29 0 0 29
Total 1,392 92 78 1,562
CT, computed tomography; SPN, solitary pulmonary nodule; 
GGO, pure ground glass opacities.
The only bias of our study is the rigid preoperative lung 
cancer selection of patients that reduced futile thoracotomies 
below 10–30% of the cases reported in the literature.
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